Synthetic Antibodies - The Emerging Field of "Aptamers" in Diagnostics and Drug Discovery
Presented At:
LabRoots - Drug Discovery Virtual Event 2019
Presented By:
G. Thomas Caltagirone, PhD - President & CEO, Aptagen, LLC
Speaker Biography:
Dr. Caltagirone is the President & CEO of Aptagen and has over 25 years of research and business experience in start-ups. A native of York, PA, he began his studies at the University of the Sciences in Philadelphia followed by a Ph.D. in neuroscience from Drexel University. He completed his thesis on "Proton-Sensitive Ribozyme Switches with Molecular Memory" at Yale University, and has several patents and publications under his name.
Webinar:
Synthetic Antibodies - The Emerging Field of "Aptamers" in Diagnostics and Drug Discovery
Webinar Abstract:
An aptamer (also known as a synthetic antibody) is a stable DNA, RNA, or peptide ligand that binds with high affinity and specificity to targets such as small molecules, peptides, proteins, biomarkers, cells, and tissues. Typical aptamer affinities are in the nanomolar to picomolar range for several target types. However, unlike the traditional antibody, aptamers have impressive specificities against target antigens, thereby eliminating cross-reactivity with closely related targets and avoiding false-positive results. A classic example is an aptamer that exhibits greater than 10,000-fold binding affinity for theophylline over caffeine, which differ from one another in structure by only a single methyl group. Additional benefits of aptamers include: manufacturing costs and time are all lower compared to that of monoclonal antibody production. Once the aptamer (nucleic acid) sequence is known, the aptamer can be easily synthesized using a DNA (oligo) synthesizer. These aptamer oligos are easy to label with reporters, enzymes, or fluorescent tags. In addition, aptamers can be engineered into molecular switches or apta-switches for signal generation in a drug discovery-based assay or to produce an output in a diagnostic test.
Earn PACE/CME Credits:
1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtual-event/drug-discovery-2019)
2. Watch the webinar on YouTube above or on the LabRoots Website (https://www.labroots.com/virtual-event/drug-discovery-2019)
3. Click Here to get your PACE (Expiration date – February 27, 2021 10:30 AM) – https://www.labroots.com/credit/pace-credits/3271/third-party
LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc
Видео Synthetic Antibodies - The Emerging Field of "Aptamers" in Diagnostics and Drug Discovery канала LabRoots
LabRoots - Drug Discovery Virtual Event 2019
Presented By:
G. Thomas Caltagirone, PhD - President & CEO, Aptagen, LLC
Speaker Biography:
Dr. Caltagirone is the President & CEO of Aptagen and has over 25 years of research and business experience in start-ups. A native of York, PA, he began his studies at the University of the Sciences in Philadelphia followed by a Ph.D. in neuroscience from Drexel University. He completed his thesis on "Proton-Sensitive Ribozyme Switches with Molecular Memory" at Yale University, and has several patents and publications under his name.
Webinar:
Synthetic Antibodies - The Emerging Field of "Aptamers" in Diagnostics and Drug Discovery
Webinar Abstract:
An aptamer (also known as a synthetic antibody) is a stable DNA, RNA, or peptide ligand that binds with high affinity and specificity to targets such as small molecules, peptides, proteins, biomarkers, cells, and tissues. Typical aptamer affinities are in the nanomolar to picomolar range for several target types. However, unlike the traditional antibody, aptamers have impressive specificities against target antigens, thereby eliminating cross-reactivity with closely related targets and avoiding false-positive results. A classic example is an aptamer that exhibits greater than 10,000-fold binding affinity for theophylline over caffeine, which differ from one another in structure by only a single methyl group. Additional benefits of aptamers include: manufacturing costs and time are all lower compared to that of monoclonal antibody production. Once the aptamer (nucleic acid) sequence is known, the aptamer can be easily synthesized using a DNA (oligo) synthesizer. These aptamer oligos are easy to label with reporters, enzymes, or fluorescent tags. In addition, aptamers can be engineered into molecular switches or apta-switches for signal generation in a drug discovery-based assay or to produce an output in a diagnostic test.
Earn PACE/CME Credits:
1. Make sure you’re a registered member of LabRoots (https://www.labroots.com/virtual-event/drug-discovery-2019)
2. Watch the webinar on YouTube above or on the LabRoots Website (https://www.labroots.com/virtual-event/drug-discovery-2019)
3. Click Here to get your PACE (Expiration date – February 27, 2021 10:30 AM) – https://www.labroots.com/credit/pace-credits/3271/third-party
LabRoots on Social:
Facebook: https://www.facebook.com/LabRootsInc
Twitter: https://twitter.com/LabRoots
LinkedIn: https://www.linkedin.com/company/labroots
Instagram: https://www.instagram.com/labrootsinc
Pinterest: https://www.pinterest.com/labroots/
SnapChat: labroots_inc
Видео Synthetic Antibodies - The Emerging Field of "Aptamers" in Diagnostics and Drug Discovery канала LabRoots
Показать
Комментарии отсутствуют
Информация о видео
Другие видео канала
![Aptamers and SELEX: The Past, The Present, and The Future](https://i.ytimg.com/vi/ZQujMqXm2wQ/default.jpg)
![Synthetic Vaccine Particles for Antigen Specific Immune Tolerance](https://i.ytimg.com/vi/NePyd3MvpWw/default.jpg)
![Cardiology in the Time of COVID-19: Thrombotic and Embolic Complications](https://i.ytimg.com/vi/gJ8txs2QIsE/default.jpg)
![Synthetic antibodies might offer a quick coronavirus treatment](https://i.ytimg.com/vi/TWups0yudjY/default.jpg)
![Application of Aptamers in the Clinical Laboratory - Geoffrey Baird, MD, PhD](https://i.ytimg.com/vi/4FV9ECPICQc/default.jpg)
![This Synthetic DNA Factory Is Building New Forms of Life](https://i.ytimg.com/vi/DxoLoOtyllU/default.jpg)
![B-Cells 2 - Antibody Production and Recombination](https://i.ytimg.com/vi/AmAa2g3fiI4/default.jpg)
![The advent of biosensor technology | Josh Windmiller | TEDxSanDiegoSalon](https://i.ytimg.com/vi/qkmyRBasoJE/default.jpg)
![CRISPR technology is now targeting RNA-based diseases | Patrick Hsu | TEDxSanDiegoSalon](https://i.ytimg.com/vi/h7YWqgXheYQ/default.jpg)
![Nicholas Dolman - High content imaging and analysis for drug discovery phenotypic assays...](https://i.ytimg.com/vi/yfOH7fuASL0/default.jpg)
![What Is the RNA World Hypothesis?](https://i.ytimg.com/vi/K1xnYFCZ9Yg/default.jpg)
![How to build synthetic DNA and send it across the internet | Dan Gibson](https://i.ytimg.com/vi/6ElobAhlQo0/default.jpg)
![Dr. Oligo 192 - DNA / RNA Oligonucleotide Synthesizer - Demo](https://i.ytimg.com/vi/GmR2UWJbGzs/default.jpg)
![Coronavirus Test: Real time RT-PCR - Animation video](https://i.ytimg.com/vi/ThG_02miq-4/default.jpg)
![Why labs are printing the coronavirus genome](https://i.ytimg.com/vi/RvyQJHKicXk/default.jpg)
![Immunology - Introduction to Antibodies](https://i.ytimg.com/vi/C_GRI3fxUWw/default.jpg)
![Understanding Aptamers in three minutes.](https://i.ytimg.com/vi/TDQETL6IgCI/default.jpg)
![Genomic Advances in Drug Discovery & Development - Lon Cardon, Ph.D.](https://i.ytimg.com/vi/BBANZxYxXM8/default.jpg)
![Immune profiling of hospitalized COVID-19 patients](https://i.ytimg.com/vi/DyGo7Zzqloc/default.jpg)
![Chimeric Antigen Receptors: From proof of concept to widely applicable clinical research solutions](https://i.ytimg.com/vi/pv7o0hFm8Ps/default.jpg)